AAPL   320.73 (+0.88%)
MSFT   182.44 (-0.44%)
FB   228.70 (+1.60%)
GOOGL   1,433.17 (-0.02%)
CGC   16.06 (-7.54%)
BABA   204.82 (-1.24%)
MU   46.77 (-2.38%)
GE   6.70 (+1.98%)
TSLA   877.85 (+5.13%)
AMD   53.34 (-0.86%)
T   31.08 (+0.71%)
ACB   13.90 (-1.28%)
GILD   74.59 (-4.16%)
DIS   118.81 (+1.29%)
NFLX   421.81 (+0.50%)
BAC   24.68 (+2.32%)
AAPL   320.73 (+0.88%)
MSFT   182.44 (-0.44%)
FB   228.70 (+1.60%)
GOOGL   1,433.17 (-0.02%)
CGC   16.06 (-7.54%)
BABA   204.82 (-1.24%)
MU   46.77 (-2.38%)
GE   6.70 (+1.98%)
TSLA   877.85 (+5.13%)
AMD   53.34 (-0.86%)
T   31.08 (+0.71%)
ACB   13.90 (-1.28%)
GILD   74.59 (-4.16%)
DIS   118.81 (+1.29%)
NFLX   421.81 (+0.50%)
BAC   24.68 (+2.32%)
AAPL   320.73 (+0.88%)
MSFT   182.44 (-0.44%)
FB   228.70 (+1.60%)
GOOGL   1,433.17 (-0.02%)
CGC   16.06 (-7.54%)
BABA   204.82 (-1.24%)
MU   46.77 (-2.38%)
GE   6.70 (+1.98%)
TSLA   877.85 (+5.13%)
AMD   53.34 (-0.86%)
T   31.08 (+0.71%)
ACB   13.90 (-1.28%)
GILD   74.59 (-4.16%)
DIS   118.81 (+1.29%)
NFLX   421.81 (+0.50%)
BAC   24.68 (+2.32%)
AAPL   320.73 (+0.88%)
MSFT   182.44 (-0.44%)
FB   228.70 (+1.60%)
GOOGL   1,433.17 (-0.02%)
CGC   16.06 (-7.54%)
BABA   204.82 (-1.24%)
MU   46.77 (-2.38%)
GE   6.70 (+1.98%)
TSLA   877.85 (+5.13%)
AMD   53.34 (-0.86%)
T   31.08 (+0.71%)
ACB   13.90 (-1.28%)
GILD   74.59 (-4.16%)
DIS   118.81 (+1.29%)
NFLX   421.81 (+0.50%)
BAC   24.68 (+2.32%)
Log in

NASDAQ:AKCAAkcea Therapeutics Stock Price, Forecast & News

$14.93
+0.03 (+0.20 %)
(As of 06/1/2020 12:11 PM ET)
Add
Compare
Today's Range
$14.60
Now: $14.93
$15.18
50-Day Range
$14.15
MA: $15.90
$18.00
52-Week Range
$8.00
Now: $14.93
$25.66
Volume76,435 shs
Average Volume196,903 shs
Market Capitalization$1.51 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.24
Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.
Read More
Akcea Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.16 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKCA
CUSIPN/A
Phone617-207-0202

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$488.54 million
Cash Flow$0.51 per share
Book Value$5.78 per share

Profitability

Net Income$40.77 million

Miscellaneous

Employees248
Market Cap$1.51 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive AKCA News and Ratings via Email

Sign-up to receive the latest news and ratings for AKCA and its competitors with MarketBeat's FREE daily newsletter.

Akcea Therapeutics (NASDAQ:AKCA) Frequently Asked Questions

How has Akcea Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Akcea Therapeutics' stock was trading at $13.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AKCA shares have increased by 11.1% and is now trading at $14.93. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Akcea Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Akcea Therapeutics.

When is Akcea Therapeutics' next earnings date?

Akcea Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Akcea Therapeutics.

How were Akcea Therapeutics' earnings last quarter?

Akcea Therapeutics Inc (NASDAQ:AKCA) released its earnings results on Tuesday, May, 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.03. The company had revenue of $16.07 million for the quarter, compared to the consensus estimate of $34.85 million. Akcea Therapeutics had a negative return on equity of 6.70% and a negative net margin of 8.59%. The company's revenue was down 90.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.15 earnings per share. View Akcea Therapeutics' earnings history.

What price target have analysts set for AKCA?

4 equities research analysts have issued 1 year price objectives for Akcea Therapeutics' shares. Their forecasts range from $24.00 to $41.00. On average, they anticipate Akcea Therapeutics' stock price to reach $34.67 in the next year. This suggests a possible upside of 132.2% from the stock's current price. View analysts' price targets for Akcea Therapeutics.

Has Akcea Therapeutics been receiving favorable news coverage?

News articles about AKCA stock have been trending somewhat positive recently, InfoTrie reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Akcea Therapeutics earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutAkcea Therapeutics.

Who are some of Akcea Therapeutics' key competitors?

What other stocks do shareholders of Akcea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Achaogen (AKAO), Ciena (CIEN), AMC Entertainment (AMC), Apollo Global Management (APO), Associated British Foods (ABF) and Chaarat Gold (CGH).

Who are Akcea Therapeutics' key executives?

Akcea Therapeutics' management team includes the following people:
  • Ms. Paula Soteropoulos, CEO & Director (Age 51)
  • Mr. Michael F. MacLean, Chief Financial Officer (Age 53)
  • Dr. Louis St. Laurence O'Dea FRCPC, MB, BCh, BAO, FRCP(C), Chief Medical Officer (Age 68)
  • Ms. Sarah Boyce, Pres & Director (Age 47)
  • Mr. Jeffrey M. Goldberg, Chief Operating Officer (Age 46)

When did Akcea Therapeutics IPO?

(AKCA) raised $125 million in an initial public offering on Friday, July 14th 2017. The company issued 9,600,000 shares at $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets was co-manager.

What is Akcea Therapeutics' stock symbol?

Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."

Who are Akcea Therapeutics' major shareholders?

Akcea Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (1.79%), State Street Corp (0.67%), Geode Capital Management LLC (0.27%), Alps Advisors Inc. (0.17%), Nuveen Asset Management LLC (0.08%) and Russell Investments Group Ltd. (0.07%). Company insiders that own Akcea Therapeutics stock include Damien Mcdevitt, Jeff Marc Goldberg, Joshua F Patterson, Kyle Jenne, Paula Soteropoulos and Sarah Boyce. View institutional ownership trends for Akcea Therapeutics.

Which institutional investors are selling Akcea Therapeutics stock?

AKCA stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, BlackRock Inc., Russell Investments Group Ltd., Alps Advisors Inc., Tudor Investment Corp Et Al, Morgan Stanley, Wells Fargo & Company MN, and Deutsche Bank AG. Company insiders that have sold Akcea Therapeutics company stock in the last year include Damien Mcdevitt, Joshua F Patterson, Kyle Jenne, and Sarah Boyce. View insider buying and selling activity for Akcea Therapeutics.

Which institutional investors are buying Akcea Therapeutics stock?

AKCA stock was purchased by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Geode Capital Management LLC, Dynamic Technology Lab Private Ltd, Nuveen Asset Management LLC, Aigen Investment Management LP, State Street Corp, Mackenzie Financial Corp, and SG Americas Securities LLC. View insider buying and selling activity for Akcea Therapeutics.

How do I buy shares of Akcea Therapeutics?

Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Akcea Therapeutics' stock price today?

One share of AKCA stock can currently be purchased for approximately $14.93.

How big of a company is Akcea Therapeutics?

Akcea Therapeutics has a market capitalization of $1.51 billion and generates $488.54 million in revenue each year. The company earns $40.77 million in net income (profit) each year or $0.48 on an earnings per share basis. Akcea Therapeutics employs 248 workers across the globe.

What is Akcea Therapeutics' official website?

The official website for Akcea Therapeutics is www.akceatx.com.

How can I contact Akcea Therapeutics?

Akcea Therapeutics' mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company can be reached via phone at 617-207-0202 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.